News >

Landgren Explains Evolving Myeloma Landscape

Angelica Welch
Published: Friday, Apr 20, 2018

C. Ola Landgren, MD, PhD

C. Ola Landgren, MD, PhD
The treatment paradigm of multiple myeloma has been flooded with new agents and combinations, as well as the potential for chimeric antigen receptor (CAR) T-cell therapy, explains C. Ola Landgren, MD, PhD.

State of the Science Summit™ on Hematologic Malignancies. In an interview during the meeting, Landgren shared his insight on CAR T-cell therapy, sequencing, and triplet and quadruplet regimens in myeloma.

OncLive: Can you please discuss your presentation?

Landgren: I gave a presentation on the treatment landscape for patients with relapsed/refractory multiple myeloma. As illustrated in my lecture, there are many options in terms of treatment. I spoke about the fact that relapse varies greatly from patient to patient. It can be a biochemical or a symptomatic relapse. Depending on how relapse presents, there are different options to consider.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication